



BIOPOL CHEMICALS LIMITED
(Formerly known as Biopol Chemicals Private Limited)

CIN NO. : L20297GJ2023PLC140117

Regd. Office : D-211, 2nd Floor, Block-D, Sumel Business Park-6
Nr. Dudheshwar Circle, Dudheshwar Tavdipura Ahmedabad.
Ahmedabad City, Gujarat - 380004, India

Email id : info@biopolchemicals.com

Contact No. : +91-9147076778

Website : www.biopolchemicals.com

Date: April 30, 2026

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051

NSE SYMBOL: BIOPOL
ISIN: INE0XW001014

Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Subject: Outcome of Meeting of Board of Directors held today i.e. Thursday, April 30, 2026 for consideration and approval of Audited Financial Results for the Half Year and Year ended on March 31, 2026

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we wish to inform you that the Board of Directors of **Biopol Chemicals Limited** at its meeting held today, i.e., Thursday, April 30, 2026, inter alia, has considered and approved the following:

1. Audited Financial Results:

The Board has approved the Audited Standalone Financial Results of the Company for the half year and financial year ended March 31, 2026, along with the Audit Report issued by the Statutory Auditors.

We hereby confirm that M/s. M B Jajodia & Associates, Chartered Accountants (Firm Registration No. 0139647W), Statutory Auditors of the Company, have issued an Audit Report with an unmodified opinion on the aforesaid financial results.

In terms of Regulation 33(3)(d) of the SEBI LODR Regulations, the declaration regarding unmodified opinion and Audited Financial Results for the, half year and Year ended on March 31, 2026 is enclosed herewith (as Annexure-A) for your information and record.

2. Confirmation regarding Large Corporate Criteria:

We hereby confirm that the Company does not fall under the category of ‘Large Corporate’ as per the applicability criteria specified under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, for the financial year ended March 31, 2026.



BIOPOL CHEMICALS LIMITED

(Formerly known as Biopol Chemicals Private Limited)

CIN NO. : L20297GJ2023PLC140117

Regd. Office : D-211, 2nd Floor, Block-D, Sumel Business Park-6

Nr. Dudheshwar Circle, Dudheshwar Tavdipura Ahmedabad.

Ahmedabad City, Gujarat - 380004, India

Email id : info@biopolchemicals.com

Contact No. : +91-9147076778

Website : www.biopolchemicals.com

The above matters have been duly approved by the Board of Directors at their meeting which commenced at 11:30 A.M. and concluded at 01:20 P.M.

This intimation is also being made available on the website of the Company at www.biopolchemicals.com.

Kindly please take the information in your records.

Thanking You,

Yours Faithfully,

For, BIOPOL CHEMICALS LIMITED

SANTANU SARKAR

Managing Director

DIN: 01245213

Encl: a/a



BIOPOL CHEMICALS LIMITED

(Formerly known as Biopol Chemicals Private Limited)

CIN NO. : L20297GJ2023PLC140117

Regd. Office : D-211, 2nd Floor, Block-D, Sumel Business Park-6

Nr. Dudheshwar Circle, Dudheshwar Tavdipura Ahmedabad.

Ahmedabad City, Gujarat - 380004, India

Email id : info@biopolchemicals.com

Contact No. : +91-9147076778

Website : www.biopolchemicals.com

Annexure – A

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai – 400 051

NSE SYMBOL: BIOPOL
ISIN: INE0XW001014

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 33(3)(d) of the Listing Regulations, as amended from time to time, we hereby declare that Statutory Auditor of Biopol Chemicals Limited, M/s, M B Jajodia & Associates, Chartered Accountants (Firm Registration Number: 0139647W), have submitted their Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended March 31, 2026, as approved by the Board at its Meeting held on April 30, 2026.

Request you to kindly take the same on record.

Thank You.

Yours Sincerely,

For, BIOPOL CHEMICALS LIMITED

SANTANU SARKAR
Managing Director
DIN: 01245213



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF THE HALF YEARLY AND YEARLY FINANCIAL RESULTS

To the Member of,
BIOPOL CHEMICALS LIMITED,

Opinion


We have audited the accompanying Statement of Financial Results (the "statement of Audited Financial Results") of Biopol Chemicals Limited ("the Company") for the half year and year ended on 31st March, 2026, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015").

In our opinion and to the best of our information and according to the explanations given to us the Statement:

- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations in this regard; and
- gives a true and fair view in conformity with the recognition and measurement principles laid down in Accounting Standards and other accounting principles generally accepted in India for the net profit and other financial information of the company for the half year and year ended 31st March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial Results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have





obtained is sufficient and appropriate to provide a basis for our opinion on Financial Results.

Management's Responsibilities for the Financial Results


The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial Results that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the AS and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the board of director's are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of director's either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could





reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results, or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.





We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The figure for both the half years ended 31st March 2026 & 31st March 2025 are the balancing figures between the audited figures in respect of full financial year and the published audited year to date figures up to first half of the relevant financial year.

For and on behalf of
M B JAJODIA & ASSOCIATES
Chartered Accountants
FRN: 0139647W
Peer Review No.: 015630

Manoj Jajodia
Partner

Membership number: 162116

Place: Ahmedabad

Date: 30-04-2026

UDIN: 26162116QHXCXX3845



Biopol Chemicals Limited (Formerly known as Biopol Chemicals Private Limited)

Registered Office: D-211, 2 Floor, Block-D, Sumel Business Park-6, Nr Dudheshwar Circle, Ahmedabad, Gujarat, India, 380004

Head Office: Unit no 2ES3B1 2nd Floor Mani Casadona Street No 372 Action Area 1, IIFNewtown Alia University, New Town, North 24 Parganas, New Town, WestBengal, India, 700156

CIN: L20297GJ2023PLC140117

Statement of Audited Financial Results for the Half year and Year Ended 31-Mar-2026

(In Lakhs)

Particulars	Half Year Ended			Year Ended	
	31-Mar-2026	30-Sep-2025	31-Mar-2025	31-Mar-2026	31-Mar-2025
	Audited	Audited	Audited	Audited	Audited
Revenue from Operations	4,948.60	3,165.73	3,384.68	8,114.33	4,922.13
Other Income	12.55	10.28	-	22.83	-
Total Income	4,961.15	3,176.01	3,384.68	8,137.16	4,922.13
Expenses					
Cost of Material Consumed	2,992.61	1,378.11	1,408.72	4,370.72	1,882.72
Purchases of Stock in Trade	1,079.35	1,078.79	1,537.65	2,158.14	2,478.26
Change in Inventories of Work in Progress, Finished Goods and Stock in Trade	(266.76)	47.93	(146.46)	(218.82)	(332.18)
Employee Benefit Expenses	96.82	82.03	52.99	178.85	103.84
Finance Costs	98.65	53.43	37.61	152.08	60.47
Depreciation and Amortization Expenses	6.11	3.72	3.86	9.83	9.19
Other Expenses	143.13	137.40	86.60	280.53	141.78
Total expenses	4,149.91	2,781.41	2,980.97	6,931.32	4,344.09
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	811.24	394.60	403.71	1,205.84	578.04
Exceptional Item	-	-	-	-	-
Profit/(Loss) before Extraordinary Item and Tax	811.24	394.60	403.71	1,205.84	578.04
Extraordinary Item	-	-	-	-	-
Profit/(Loss) before Tax	811.24	394.60	403.71	1,205.84	578.04
Tax Expenses					
- Current Tax	208.09	101.43	103.91	309.53	147.78
- Deferred Tax	(0.84)	(0.26)	(0.28)	(1.10)	(0.97)
- MAT Credit Entitlement	-	-	-	-	-
- Prior Period Taxes	-	-	-	-	-
Profit/(Loss) for the Period from Continuing Operations	603.98	293.42	300.09	897.41	431.23
Profit/(loss) from Discontinuing Operation (before tax)	-	-	-	-	-
Tax Expenses of Discontinuing Operation	-	-	-	-	-
Profit/(loss) from Discontinuing Operation (after tax)	-	-	-	-	-
Profit/(Loss) for the period	603.98	293.42	300.09	897.41	431.23
Paid-up Share Capital (Face Value per Share Rs.10 each)	1,080.54	791.10	791.10	791.10	791.10
Reserves Excluding Revaluation Reserve	-	-	-	3,911.55	567.79
Earnings Per Share (Face Value per Share Rs.10 each)					
-Basic (In Rs)	6.18	3.71	3.07	10.83	5.45
-Diluted (In Rs)	6.18	3.71	3.07	10.83	5.45



Notes:-

1	The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on April 30, 2026.
2	As the Company operates in a single business segment, accordingly, the reporting under AS17 "Segment reporting" are Not applicable to the company.
3	The Statutory Auditors of the Company have carried out the Audit of the above financial results of the Company and have expressed an unmodified opinion on these results.
4	Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.
5	As the company is listed on SME Platform of NSE, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015
6	The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.
7	The results for the Half Year and year ended March 31, 2026 are available on the National Stock Exchange of India Limited website (URL: www.nseindia.com) and also on the company's website (https://biopolchemicals.com/).
8	There are no investor complaints received/pending as on 31 st March, 2026.
9	Internal Audit of Financial results for the Half Year ended on 31/03/2026 has been conducted by the Internal Auditor of the Company.
10	The figure for the both Half Year ended 31 st March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published audited year to date figures of the relevant financial year.

For & On behalf of board of, Biopol Chemicals Limited



Santanu Sarkar

Santanu Sarkar
Managing Director
DIN: 01245213

Place : Ahmedabad
Date: 30-04-2026

Biopol Chemicals Limited (Formerly known as Biopol Chemicals Private Limited)

Registered Office: D-211, 2 Floor, Block-D, Sumel Business Park-6, Nr Dudheshwar Circle, Ahmedabad, Gujarat, India, 380004

Head Office: Unit no 2ES3B1 2nd Floor Mani Casadona Street No 372 Action Area 1, IIFNewtown Alia University, New Town,

North 24 Parganas, New Town, WestBengal, India, 700156

CIN: L20297GJ2023PLC140117

Audited Statement of Asset and Liabilities as at 31-Mar-2026*(In Lakhs)*

Particulars	31-Mar-2026	31-Mar-2025
I. EQUITY AND LIABILITIES		
(1) Shareholders' Funds		
(a) Share Capital	1,080.54	791.10
(b) Reserves and Surplus	3,911.55	567.79
(c) Money Received against Share Warrants	-	-
Total	4992.09	1,358.89
(2) Share application money pending allotment	-	-
(3) Non-current liabilities		
(a) Long-term Borrowings	505.55	64.01
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Non-current liabilities	-	-
(d) Long-term Provisions	6.77	-
Total	512.32	64.01
(4) Current liabilities		
(a) Short-term Borrowings	340.94	704.52
(b) Trade Payables		
Total outstanding dues to Msme	18.61	14.96
Total outstanding dues to Other than Msme	624.90	845.14
(c) Other Current Liabilities	48.88	32.34
(d) Short-term Provisions	439.79	147.78
Total	1,473.12	1,744.74
Total Equity and Liabilities	6,977.53	3,167.64
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Capital WIP and Intangible Assets		
(i) Property, Plant and Equipment	1,423.84	25.45
(ii) Capital Work-in-progress	12.00	-
(iii) Intangible Assets	0.35	0.33
(iv) Intangible Assets under Development	-	-
(b) Non-current Investments	-	-
(c) Deferred Tax Assets (net)	3.65	0.91
(d) Long-term Loans and Advances	35.90	-
(e) Other Non-current Assets	-	-
Total	1,475.74	26.69
(2) Current assets		
(a) Current investments	-	-
(b) Inventories	1,960.76	1,181.44
(c) Trade Receivables	2,778.69	1,665.64
(d) Cash and cash equivalents	51.84	114.83
(e) Short-term Loans and Advances	482.97	72.44
(f) Other Current Assets	227.53	106.60
Total	5,501.80	3,140.95
Total Assets	6,977.53	3,167.64

For & On behalf of board of, Biopol Chemicals Limited

*Santanu Sarkar*Santanu Sarkar
Managing Director

DIN: 01245213

Place : Ahmedabad

Date: 30-04-2026

Biopol Chemicals Limited (Formerly known as Biopol Chemicals Private Limited)
Registered Office: D-211, 2 Floor, Block-D, Sumel Business Park-6, Nr Dudheshwar Circle,
Ahmedabad, Gujarat, India, 380004

Head Office: Unit no 2ES3B1 2nd Floor Mani Casadona Street No 372 Action Area 1, IIFNewtown Alia University, New
Town, North 24 Parganas, New Town, WestBengal, India, 700156

CIN: L20297GJ2023PLC140117

Audited Statement Cash Flow for the year Ended 31-Mar-2026

(In Lakhs)

Particulars	31-Mar-2026	31-Mar-2025
(A) CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax and Extra ordinary Items	1,205.84	578.04
Adjustments for:		
Depreciation and Amortisation Expense	9.83	9.19
Finance Costs	152.08	60.47
Interest Income	(3.16)	-
Gratuity Expense	1.16	-
Unrealised Forex Gain	(3.25)	-
Operating Profit before working capital changes	1,362.50	647.71
Changes in Working Capital		
(Increase)/Decrease in Trade Receivables	(1,109.80)	(686.03)
(Increase)/Decrease in Inventories	(779.32)	(568.14)
(Increase)/Decrease in Short Term Loans and Advances	(410.53)	(52.44)
Increase/(Decrease) in other Current Assets	(110.47)	(22.28)
Increase/(Decrease) in Trade Payables	(216.59)	466.36
Increase/(Decrease) in other Current liabilities	16.54	16.38
Cash (Used in)/Generated from Operating Activities	(1,247.68)	(198.45)
Less :- Income Tax paid(Net)	(28.92)	42.91
Net Cash (Used in)/Generated from Operating Activities	(1,276.60)	(241.37)
Extraordinary items	-	-
Net cash generated from / (used in) Operating Activities.....A	(1,276.60)	(241.37)
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Interest Received	3.16	-
Purchase of Property, Plant and Equipment	(1,407.99)	(2.43)
Purchase of Capital WIP	(12.00)	-
Purchase of Intangible Asset	(0.25)	-
Increase/(Decrease) in Long Term Loans and Advances	(35.90)	-
Net cash generated from / (used in) Investing Activities.....B	(1,452.98)	(2.43)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Share Capital (IPO)	3,125.95	-
Less:- Issue Cost	(385.26)	-
Net Proceeds from issue of Share Capital	2,740.69	-
Proceeds from Short Term Borrowings	150.04	346.86
Repayment of Short Term Borrowings	(681.25)	-
Repayment of Long Term Borrowings	(3.72)	-
Proceeds From Long Term Borrowings	612.89	64.01
Interest and Finance Charges Paid	(152.08)	(60.47)
Net cash generated from / (used in) Financing Activities.....C	2,666.58	350.40
Net increase in cash and cash equivalents (A+B+C)	(62.99)	106.60
Opening Balance of Cash and Cash Equivalents	114.83	8.23
Closing Balance of Cash and Cash Equivalents	51.84	114.83



Components of cash and cash equivalents	31-Mar-2026	31-Mar-2025
Cash on hand	8.75	2.27
Cheques, drafts on hand	-	-
Balances with banks in current accounts	43.08	112.56
Bank Deposit having maturity of less than 3 months	-	-
Others	-	-
Cash and cash equivalents as per Cash Flow Statement	51.84	114.83

For & On behalf of board of, Biopol Chemicals Limited



Santanu Sarkar

Santanu Sarkar
Managing Director
DIN: 01245213

Place : Ahmedabad
Date: 30-04-2026

Disclosure of Related Party Transactions for the Half Year Ended March 31, 2026

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes		
1	Biopol Chemicals Limited	AALCB 5111 B	Santanu Sarkar		Managing Director	Remuneration Payable	30,00,000.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	Biopol Chemicals Limited	AALCB 5111 B	Santanu Sarkar		Managing Director	Unsecured Loan Accepted	1,70,00,000.00	-	-	-	-	-	1,26,14,800.00	-	-	-	-	-	-	-	-	-	-	-	-	-
3	Biopol Chemicals Limited	AALCB 5111 B	Santanu Sarkar		Managing Director	Unsecured Loan Repaid	43,85,200.00	-	-	-	-	-	1,26,14,800.00	-	-	-	-	-	-	-	-	-	-	-	-	-
4	Biopol Chemicals Limited	AALCB 5111 B	Vandan Vij Sarkar		Spouse of Santanu Sarkar (Salary)	Remuneration Payable	3,00,000.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	Biopol Chemicals Limited	AALCB 5111 B	Vedant Sarkar		Whole time Director	Remuneration Payable	24,00,000.00	-	-	-	-	11,87,200.00	3,03,550.00	-	-	-	-	-	-	-	-	-	-	-	-	-
6	Biopol Chemicals Limited	AALCB 5111 B	Sandip Choudhury		Chief Financial Officer	Remuneration Payable	1,76,700.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	Biopol Chemicals Limited	AALCB 5111 B	Deepthi Nama		Company Secretary	Remuneration Payable	1,50,000.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

For & On behalf of board of, Biopol Chemicals Limited



Santanu Sarkar
Santanu Sarkar
 Managing Director
 DIN: 01245213